ReviewJournal of clinical medicine2022
Mediators of Amylin Action in Metabolic Control.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.Diabetes, obesity & metabolism · 2026Trial
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Molecular metabolism · 2025Trial
- QBP1 Peptide as a Potential Anti-Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intrathecal amylin reverses morphine tolerance through site-specific DNA methylation of Pdyn and Bdnf promoters in rats.Scientific reports · 2026Article
- Hypothalamus-liver talks: whispers in the language of metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- Not only gut feelings: pancreatic hormone, amylin, controls emotionality and sociability, in a sex divergent manner.Translational psychiatry · 2026Article
- Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects.Molecular diversity · 2026Review
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.Journal of medicinal chemistry · 2025Article
- Review
- Amylin receptor subunit interactions are modulated by agonists and determine signaling.Science signaling · 2025Article
- Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis.World journal of stem cells · 2025Article
- Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Ventral tegmental area amylin / calcitonin receptor signaling suppresses feeding and weight gain in female rats.Neuroscience research · 2025Article
- The role of amylin, a gut-brain axis hormone, in metabolic and neurological disorders.FASEB bioAdvances · 2025Review
- Medical Management of Obesity: Current Trends and Future Perspectives.Methodist DeBakey cardiovascular journal · 2025Review
- Rodent islet amyloid polypeptide (IAPP) selectively enhances GABAFrontiers in cellular neuroscience · 2025Article
- Hippocampal Leptin Resistance and Cognitive Decline: Mechanisms, Therapeutic Strategies and Clinical Implications.Biomedicines · 2024Review
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.Nature metabolism · 2024Review
- Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.Pharmacology research & perspectives · 2024Review
- NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin.Journal of medicinal chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Amylin (also called islet amyloid polypeptide (IAPP)) is a pancreatic beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli. The last 35 years of intensive research have shown that amylin exerts important physiological effects on metabolic control. Most importantly, amylin is a physiological control of meal-ending satiation, and it limits the rate of gastric emptying and reduces the secretion of pancreatic glucagon, in particular in postprandial states. The physiological effects of amylin and its analogs are mediated by direct brain activation, with the caudal hindbrain playing the most prominent role. The clarification of the structure of amylin receptors, consisting of the calcitonin core receptor plus receptor-activity modifying proteins, aided in the development of amylin analogs with a broad pharmacological profile. The general interest in amylin physiology and pharmacology was boosted by the finding that amylin is a sensitizer to the catabolic actions of leptin. Today, amylin derived analogs are considered to be among the most promising approaches for the pharmacotherapy against obesity. At least in conjunction with insulin, amylin analogs are also considered important treatment options in diabetic patients, so that new drugs may soon be added to the only currently approved compound pramlintide (Symlin
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.